Linden Thomas Advisory Services, LLC

Position in LGND — Ligand Pharmaceuticals Inc

CIK 1965702 Charlotte, NC

Position in LGND

as of Jun 30, 2026 · filed Jul 16, 2026 Compact

Position Value

$3,140,354

-$187,611 QoQ

Shares Held

9,935

-40.4% QoQ

Ownership

0.050%

of shares outstanding

% of Portfolio

0.25%

of 13F equity value

Holder Rank

#12

of 82 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

Linden Thomas Advisory Services, LLC holds $36,440,714 across 14 Biotechnology names. LGND ranks #6 (8.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	CPRX	Catalyst Pharmaceuticals, Inc.	176,004	$5,531,805
2	INCY	Incyte Corp	46,507	$5,272,033
3	VRTX	Vertex Pharmaceuticals Inc / Ma	8,103	$4,025,003
4	REGN	Regeneron Pharmaceuticals, Inc.	5,106	$3,183,795
5	EXEL	Exelixis, Inc.	57,943	$3,152,678
6	LGND	Ligand Pharmaceuticals Inc This page	9,935	$3,140,354
7	CORT	Corcept Therapeutics Inc	34,641	$3,012,034
8	VCEL	Vericel Corp	56,051	$2,493,708

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,140,354	9,935	-40.4%	Shares	Sole	2026-07-16
2026-03-31	$3,327,965	16,669	+0.6%	Shares	Sole	2026-04-10
2025-12-31	$3,133,835	16,575	-1.4%	Shares	Sole	2026-01-16
2025-09-30	$2,977,014	16,806	+0.1%	Shares	Sole	2025-11-06
2025-06-30	$1,908,914	16,792	-1.0%	Shares	Sole	2025-07-31
2025-03-31	$1,783,069	16,959	-0.3%	Shares	Sole	2025-04-30
2024-12-31	$1,822,407	17,008	-0.1%	Shares	Sole	2025-01-21
2024-09-30	$1,704,332	17,028	-0.5%	Shares	Sole	2024-10-17
2024-06-30	$1,441,857	17,112	+1.6%	Shares	Sole	2024-07-10
2024-03-31	$1,231,077	16,841	+2.7%	Shares	Sole	2024-04-30
2023-12-31	$1,170,788	16,393	-2.3%	Shares	Sole	2024-02-01
2023-09-30	$1,005,397	16,779	-0.2%	Shares	Sole	2023-10-20
2023-06-30	$1,211,856	16,808	—	Shares	Sole	2023-07-27
No filing history on record for this holder in this stock.